Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic
At Tessa Therapeutics, the big idea has been to adapt virus-specific T cells (VST) to target virally-associated tumors, and swarm cancer cells. Researchers believe these …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
